Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 SDH Gene Mutation clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07434843
PH 2 Pemigatinib in SDH-deficient GIST
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)
Gender: All
Ages: 18 Years - Any
Updated: 2026-02-27
1 state
NCT06408402
Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers
The primary objective of the PGL.EXPO-2 study is to test the hypothesis that exposure (occupational, environmental and/or domestic) to succinate dehydrogenase inhibitors (SDHi) could contribute to tumor emergence in subjects carrying a germline mutation in one of the SDHx genes.The primary endpoint will be the proportion of subjects (cases or controls) exposed to SDHi and the association with paraganglioma risk. In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study
Gender: All
Ages: 18 Years - Any
Updated: 2024-05-10